MGMT and glioblastoma: As previously described with other morpholino oligonucleotides, MGMT knockdown achieved with a single dose of AMONs using our approach was transient.69 In the context of glioblastoma therapy, this transient MGMT knockdown is ideal for timing therapy to achieve peak knockdown with the alkylating chemotherapy, thus limiting the potential risks associated with systemic and persistent suppression of this vital DNA repair mechanism.